A new mesothelioma treatment called MORAb-009 is entering a Phase II study. This study will take place globally and should have around 86 mesothelioma patients. The study will test MORAb-009 as a combination therapy with existing chemotherapies. Locally advanced malignant pleural mesothelioma will be the primary form that the drug will treat and be tested on.
MORAb-009 is a monoclonal antibody that blocks mesothelin and boosts the immune system. Mesothelin is a cell protein that allows tumors to attach metastatize and grow. By blocking this protein, MORAb-009 keeps tumors from growing. In addition, it stimulates the immune system to attack the tumor cells. This could be a very helpful new treatment.
If you or someone you know has been diagnosed with mesothelioma, contact the mesothelioma attorneys of Williams Kherkher at 800-781-3955.